Loading
FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins. Required for the development of B cells, and dendritic cells (DCs).
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Crenolanib, Ponatinib, Sunitinib and Lestaurtinib and others. Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.82, affected pathway 0.83, animal model 0.41, genetic association 0.00).
In plain words · FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
FLT3LG (Fms-related tyrosine kinase 3 ligand) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Acute myeloid leukaemia.
Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins.
No product in this corpus aims at FLT3LG yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA FLT3LG: RNA low tissue specificity; blood lineage lineage enriched (T-cells 172 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas FLT3LG tissue; Open Targets ENSG00000090554 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Hannum et al, Nature, 1994, "Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs". Source.
Sources: HGNC HGNC:3766 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49771 (protein name, function text, keywords and locations (REST API)); CIViC gene FLT3LG (2 evidence items, 0 assertions, 1 variants; diseases: Acute Myeloid Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000090554 (association with cancer (MONDO_0004992) 0.53; (GraphQL API, CC0))
Stimulates the proliferation of early haematopoietic cells by activating FLT3. Synergises well with a number of other colony stimulating factors and interleukins. Required for the development of B cells, and dendritic cells (DCs). Location: Cell membrane; Secreted (UniProt). Locus 19q13.33 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (T-cells 172 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FLT3LG" OR ABSTRACT:"FLT3LG" OR TITLE:"fms related receptor tyrosine kinase 3 ligand" OR ABSTRACT:"fms related receptor tyrosine kinase 3 ligand" OR TITLE:"Fms-related tyrosine kinase 3 ligand" OR ABSTRACT:"Fms-related tyrosine kinase 3 ligand") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FLT3LG, not a curated reading list.